Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.43 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392246 | 1.00 | MAP2K1 (0.49) | MAP2K1MAP2K2KCNH2MAP2K5EIF2AK1 | |
| SCHEMBL393216 | 0.89 | MAP2K1 (0.51) | MAP2K1MAP2K2KCNH2MAP2K5EIF2AK1 | |
| SCHEMBL393217 | 0.89 | MAP2K1 (0.51) | MAP2K1MAP2K2KCNH2MAP2K5EIF2AK1 | |
| SCHEMBL388611 | 0.89 | MAP2K1 (0.50) | MAP2K1MAP2K2KCNH2MAP2K5EIF2AK1 | |
| SCHEMBL390659 | 0.87 | MAP2K1 (0.59) | MAP2K1MAP2K2KCNH2MAP2K5EIF2AK1 | |
| SCHEMBL390658 | 0.87 | MAP2K1 (0.59) | MAP2K1MAP2K2KCNH2MAP2K5EIF2AK1 | |
| SCHEMBL393966 | 0.87 | MAP2K1 (0.64) | MAP2K1MAP2K2KCNH2MAP2K5EIF2AK1 | |
| SCHEMBL393004 | 0.87 | MAP2K1 (0.58) | MAP2K1MAP2K2KCNH2MAP2K5EIF2AK1 | |
| SCHEMBL394452 | 0.87 | MAP2K1 (0.55) | MAP2K1KCNH2 | |
| SCHEMBL393965 | 0.87 | MAP2K1 (0.64) | MAP2K1MAP2K2KCNH2MAP2K5EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361905-B1 | Heterocyclic Inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2013-03-06 | — | — | EP | claimed |
| US-8101639-B2 | 6-oxo-1,6-dihydropyridine compounds as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | claimed |
| EP-1922307-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2011-12-28 | — | — | EP | claimed |
| EP-2361905-A1 | Heterocyclic Inhibitors of MEK and methods of use thereof | Array Biopharma Inc. (US) | 2011-08-31 | — | — | EP | claimed |
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-03-11 | — | — | US | claimed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | claimed |
| EP-2364973-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2361905-B1 | Heterocyclic Inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8299076-B2 | crystalline form of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; for hyperproliferative diseases, such as cancer and inflammation in mammals; crystallization under acidic condition | ARRAY BIOPHARMA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8101639-B2 | 6-oxo-1,6-dihydropyridine compounds as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101611-B2 | Substituted pyridazines inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1922307-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2364973-A1 | Heterocyclic inhibitors of MEK and Methods of use thereof | Array Biopharma, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110183981-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-7732616-B2 | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-1967516-B1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | ARRAY BIOPHARMA, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1967516-A1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | Array Biopharma, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 73/4885MAP2K2 63/4885KCNH2 2738/4885 |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | BRAF, NRAS, MAP3K1 | MAP2K1 51/4885MAP2K2 45/4885KCNH2 4511/4885 |
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 73/4885MAP2K2 63/4885KCNH2 2738/4885 |
| US-20110183981-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 82/4885MAP2K2 69/4885KCNH2 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.